Why Tempus AI Skyrocketed This Week

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

08/23/2026, 7:15 AM • The Motley Fool

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

08/22/2026, 8:19 AM • The Motley Fool

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.

08/22/2026, 8:05 AM • The Motley Fool

Why Moderna Stock Skyrocketed Today

Moderna and Merck announced positive Phase 3 clinical trial results for intismeran, an mRNA-based cancer therapy designed to activate anti-tumor immune responses in melanoma patients. The experimental treatment met its primary endpoint of recurrence-free survival when combined with Merck's Keytruda immunotherapy. The companies plan to present additional data and seek regulatory approval, positioning them to capture a larger share of the $275 billion global oncology market by 2030.

08/19/2026, 8:07 PM • The Motley Fool

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

Moderna and Merck announced successful Phase 3 trial results for a personalized mRNA cancer vaccine combined with Merck's Keytruda immunotherapy. The treatment showed melanoma patients experienced longer periods before cancer recurrence and reduced spread compared to Keytruda alone. This marks the first Phase 3 success for mRNA cancer therapy and individualized neoantigen therapy, with both companies planning to present findings to regulators.

08/19/2026, 12:34 PM • The Motley Fool

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Bristol-Myers Squibb are compared as dividend-paying pharmaceutical investments. AbbVie shows stronger revenue growth (8.6% YoY) driven by Skyrizi and Rinvoq, while Bristol-Myers Squibb faces patent cliff headwinds despite trading at a significant valuation discount. The article recommends AbbVie for long-term investors due to its focused operations, accelerating neuroscience portfolio, and attractive dividend, despite Bristol-Myers Squibb's recovery potential.

08/14/2026, 3:26 PM • The Motley Fool

1 Unstoppable Dividend ETF Up 26% in 2026 to Buy and Hold for the Next 20 Years

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 26% return year-to-date in 2026, significantly outperforming the S&P 500. The ETF focuses on 100 high-quality dividend-paying companies with at least 10 years of consecutive dividend payments, featuring a low 0.06% expense ratio and 3.3% dividend yield. Its portfolio emphasizes healthcare and consumer staples sectors, making it suitable for long-term buy-and-hold investors seeking stability and passive income.

07/31/2026, 10:18 AM • The Motley Fool

Prediction: This Dividend ETF Will Thrive After 20 Years No Matter What the Market Does

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as the best dividend ETF for long-term investors seeking a 20-year income strategy. Unlike the Vanguard Dividend Appreciation ETF (VIG) and iShares Core Dividend Growth ETF (DGRO), SCHD maintains better sector balance and prioritizes dividend yield and fundamental value, with top holdings in stable consumer staples like Coca-Cola, Merck, Chevron, and Procter & Gamble that will remain relevant over decades.

07/28/2026, 6:30 AM • The Motley Fool

After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

Moderna's stock has surged nearly 90% in 2026, driven by positive FDA news about its flu vaccine mRNA-1010 in June. However, the rally appears unjustified as the vaccine is unlikely to generate significant revenue ($1B by 2028) and the company faces fundamental challenges including $3.4B in operating losses over the trailing 12 months, declining revenue, and dependence on COVID vaccine sales. With a $20B+ market cap and limited compelling growth catalysts beyond the experimental cancer vaccine mRNA-4157, the stock appears overvalued for its risk profile.

07/27/2026, 4:02 PM • The Motley Fool

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

If I Were Starting My Portfolio From Scratch Today, This Is the First ETF I'd Buy

An experienced investor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as the foundational holding for a new portfolio. The ETF focuses on high-yielding dividend-growth stocks and has delivered over 12% average annualized returns over multiple periods, outperforming pure growth stocks and high-yield stocks with lower volatility.

07/26/2026, 8:30 AM • The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

07/22/2026, 4:33 PM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire